Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
X

Expedite Your Genome Editing Analysis With Our Single-Cell Solution

From gene-edited cell therapies to CRISPR-induced disease models, genome editing outcomes can be challenging to assess. Now, get the data you need, from zygosity to co-occurrence of edits and more, at single-cell resolution with Mission Bio’s end-to-end Tapestri® Genome Editing Solution. Rapidly perform CRISPR validation in your own lab – with no clonal outgrowth or bioinformatics support required.

Talk to Scientist

Why Single Cell for Genome Editing Analysis?

Genome engineering techniques, like CRISPR, result in heterogeneous editing outcomes that include variations in zygosity, off-target effects, and co-occurring multiplex edits. Measuring these outcomes accurately cannot be done by traditional sequencing without lengthy clonal outgrowth steps and hours of computational work. With the Tapestri single-cell platform you can obtain critical genome editing measurements to validate your cell therapy or disease model.

Zygosity

Co-Occurrence of Intended Targets

Co-Occurrence of On/Off Targets

Immunophenotype

Create Clear Reports To Easily Interpret Results

click to zoom

Zygosity of On-target Edits

click to zoom

Co-Occurrence of On-Target Edits

click to zoom

Genome Editing + Cell Surface Protein

SEE AN EXAMPLE REPORT

Tapestri Genome Editing Solution

Get everything you need to conduct single-cell, multi-omic analysis of gene edits in your lab with this fully-supported, all-in-one package.
  • Tapestri Instrument
  • DNA Core Kit (8 samples)
  • Custom-Designed DNA Panel (+ Optional Protein Panel)
  • Software-Based Analysis (via Portal Access or On Premise Activation)

Our streamlined Genome Editing workflow allows you to analyze an edited sample on the Tapestri platform, sequence the libraries on NGS, and then easily analyze the results using the Tapestri Genome Editing Software. The Solution can analyze knockouts (non-homologous end joining) and base edits.

You can generate essential reports with no bioinformatic expertise required. You get clear representations of your data, giving you the insights you need to move forward.

The National Institute of Standards and Technology (NIST) Genome Editing Consortium addresses the measurements and standards needed to increase confidence and lower the risk of utilizing genome editing technologies in research and commercial products. Mission Bio is a proud participating partner.

Learn More

The Tapestri Genome Editing Workflow

The end-to-end Tapestri workflow for single-cell genome editing analysis. A sample of gene-edited cells are processed on the Tapestri Platform, sequenced using NGS, and analyzed using Tapestri Genome Editing software. The assessment at single-cell resolution of on-targets, predicted off-targets, zygosity of edits, co-occurring (multiplex) edits, predicted translocations and cell-surface proteins is possible. The Solution can be used to analyze gene knockouts (via non- homologous end joining) and base edits.
  • Step 1 – Design Panel & Run Edited Samples on Tapestri®
  • Step 2 – Sequence Libraries on NGS
  • Step 3 – Software Runs Automated Analysis and Generates Intuitive Data Report

Effortlessly analyze on- and off-target effects, assess zygosity, and identify co-occurrence of edits. Our automated analysis and intuitive reports make the process easy and efficient.

CONTACT US TO ELEVATE YOUR CRISPR EXPERIMENTS TODAY!

Primary Applications

Characterization of Cell-Based Therapeutics

  • Gather indicators of CGT safety and efficacy
  • Analyze increasingly sophisticated therapies, involving multiplex edits
  • Obtain IND-enabling data
  • Consolidate assays, saving time and sample volumes
Read Technical Note

Validation of Disease Models

  • Validate CRISPR-induced disease models
  • Resolve mutational co-occurrence patterns in models
  • Identify genetic drivers of diseases over time
  • Self-generate reports with a single end-to-end solution
Read Technical Note

Functional Genomics

  • Conduct drug target validation
  • Identify base changes that confer drug resistance/sensitivity
  • Resolve genotypes from pooled CRISPR screens
  • Interrogate non-coding regions and VUS (variants of unknown significance)
Read Publication

"This multi-omic genome-editing solution will enable critical insights for gene-edited cell therapies beyond what conventional bulk analysis can offer. The automated report gives an immediate and intuitive first look at our data, something that would usually require hours of bioinformatic labor. All in all, we are better equipped to understand our editing results with this technology."

Saar Gill MD, PhD, Associate Professor of Medicine at the University of Pennsylvania

Resources

Get Started

Contact us to begin your evaluation

CONTACT US
REQUEST QUOTE